FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	_	
n. D.C. 20549	F	
III, D.O. 20040		OMB APPR

	3	,			

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

l	OMB APPROVAL									
l	OMB Number:	3235-0287								
l	Estimated average burder	1								
l	hours per response:	0.5								

Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol Onconova Therapeutics, Inc. [ ONTX ]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>Fruchtman Steven M</u>					Onconova Therapeutics, Inc. [ ONTA ]					X	Director			10% Ow	ner	
(Loot)	/Fir	n#)	Middle)								x	Officer (g	ive title		Other (sp	ecify
(Last)	(Fir	,	(Middle)		Date c 7/09/2		ransa	ction (Month	Day/Year)			President, Chief Executive Off				
3/5 PHEA	SANT RUI	N		ľ	770372	.020							,			
(Street)	(Street)															
(Street) NEWTOWN PA 18940					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person					
(City)	(Sta	ate) (	Zip)								Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially										eficially C	wned					
Date				Saction 2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.					Form: Direct		. Nature of ndirect eneficial wnership nstr. 4)			
							Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				nsu. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (	nsaction de (Instr. S. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration D	5. Date Exercisable and Expiration Date Securities Under Month/Day/Year)  7. Title and Application Securities Under Derivative Secur (Instr. 3 and 4)		d Amount of Underlying Security	unt of 8. Price of Privative		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares (Instr. 4)					
Stock Appreciation Right	\$0.56	07/09/2020		A		1,273,800		(1)	07/09/2030	Common Stock	1,273,800	\$0	1,273,8	800	D	

## **Explanation of Responses:**

1. These stock appreciation rights vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.

/s/ Mark Guerin as attorney-in-

fact

07/10/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.